

WAY



Fagron's SyrSpend® SF — A Total Solution, Providing Convenient and Efficient Oral Liquid Dosage Form

SyrSpend® SF brings added value in compounding oral suspensions — superior suspendability for more accurate dosing, better taste, extensive scientific stability data, and can improve compliance, all while reducing inventory and carrying costs.

Founded: 1980
 Employees: 50 +
 Toll-free Phone: (800) 423-6967
 Fax: (800) 339-1596
 Address: Fagron, Inc. 2400 Pilot Knob Road
 St. Paul, MN 55120
 Website: Order online at shop.fagron.us



Company Background

Fagron continuously introduces innovative products based on research done in our own R&D center. We work together with pharmacists, universities, physicians, and other healthcare providers to deliver optimized products and solutions. We continuously perform studies on our products, dedicated to providing you with the most innovative compounding solutions.

Fagron's strategy is focused on the optimization and innovation of pharmaceutical compounding. As an R&D scientific pharmaceutical compounding company, Fagron wants to widen the scope of the prescriber to provide tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist and improves the patient's quality of life.

Based in St. Paul, MN, Fagron, Inc. is part of the Fagron Group, a global market leader in pharmaceutical compounding, headquartered in the Netherlands. With over 2,000 employees in 32 countries worldwide, the Fagron Group provides over 200,000 pharmacists with superior compounding products every day.

Product Overview

SyrSpend® SF is an innovative vehicle for the compounding of oral liquid dosage forms. Based on food starch, SyrSpend® SF's superior suspending properties provide consistent, individual dosing throughout treatment. The excellent compatibility with a broad range of active pharmaceutical ingredients (APIs) and meticulous ingredient selection make SyrSpend® SF highly suitable for compounding stable tailor-made medication.

SyrSpend® SF is a quick and easy compounding option that provides pharmaceutical stability and dosage consistency with each preparation. Its light texture, safe ingredients, and neutral taste result in treatment that is comfortable and easy-to-swallow for all patient groups, from neonates to elderly. Compatible with an extensive range of APIs, you can choose the most suitable product for compounding with both acid and alkaline options.

■ Our product line consists of:

- SyrSpend® SF, a sugar-free suspending vehicle buffered to a pH of 4.2 for maximum compatibility with APIs. Preservative-free version available.

- SyrSpend® SF Alka, an easy-to-use powder for reconstitution that provides an alkaline environment for acid-labile drugs such as omeprazole.

■ Superior Suspending Technology

- Innovative, highly stable suspensions based on modified food starch.
- Formulated using only well-tolerated ingredients.
- Optimal palatability and taste-masking properties for improved compliance.
- Compatibility with a broad range of APIs.
- API stability supported by peer-reviewed scientific articles.
- Convenient vehicles for efficient and high-quality compounding.

Benefits of SyrSpend® SF

- All-in-one suspending vehicles.
- Optimizes ease of administration, mouth feel, and taste masking.
- Meticulous ingredient choice, formulated without alcohol, parabens, sorbitol, sugars, gluten, or dyes.
- Ideal for individualized dosage regimens.
- Low osmolality (<50 mOsm), minimizing gastrointestinal upset and diarrhea.
- Active Suspending Technology to hold API particles in suspension longer for more accurate and consistent dosing during treatment.
- Suitable for diabetic patients.
- Extensive and growing database of stability data.
- Produced in a GMP-certified and FDA registered facility with pharmaceutically-tested ingredients.

Stability Studies

Fagron continuously performs stability studies to provide our customers with extended beyond-use-dating. The studies are being published in renowned peer-reviewed journals. Visit fagron.us for more information.

Documented Beyond-Use-Date (BUD) in SyrSpend® SF Studied drugs include*: Acetazolamide, Allopurinol, Alprazolam, Aminophylline, Amiodarone HCl, Amlodipine Besylate, Captopril, Chloroquine Phosphate, Dapsone, Furosemide, Gabapentin, Hydrocortisone Hemisuccinate, Hydrocortisone Sodium Phosphate, Metronidazole Benzoate, Midazolam HCl, Nifedipine, Omeprazole, Oseltamivir phosphate, Phenobarbital, Phenytoin, Prednisolone Sodium Phosphate, Propranolol HCl, Pyridoxine HCl, Ranitidine HCl, Rifampicin, Simvastatin, Spironolactone, Sulfadiazine, Sulfasalazine, Tetracycline HCl, Trimethoprim, Ursodiol, Vancomycin HCl, Verapamil HCl, and Zonisamide.

*Literature references available.

Ordering Information

Contact us for information regarding SyrSpend® SF and our other innovations at fagron.us, customer.service@fagron.us, or (800) 423-6967.